TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01299389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
Study: NCT00438477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphangiography
Description: 2 lymphoscintigraphy images performed following peritumoral and subareolar injection of breast
Study: NCT04377698

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FDBA
Description: regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
Study: NCT03149991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexpiprazole
Description: Administration of up to 3mg brexpiprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: administration 6 times over two weeks of inhaled ketamine
Study: NCT00438477

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99m sulfur colloid
Description: At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.~At the time of surgery, patients receive isosulfan blue by subareolar injection.
Study: NCT03861793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALKS 4230
Description: SC injection administered in the back of the arm or the abdomen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALKS 4230
Description: SC injection administered in the back of the arm or the abdomen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an intravenous (IV) infusion over 30 minutes
Study: NCT03149991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: administration 6 times over two weeks of inhaled ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo which matches brexpiprazole in size and number of tablets per dose
Study: NCT02412150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthesia is maintained with desflurane

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Desflurane
Description: Anesthesia is maintained with desflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thyroidectomy
Description: The aim of this study is evaluation of effect of dexmedetomidine on emergence response and postoperative outcome after thyroidectomy
Study: NCT00633750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: matrix-assisted laser desorption ionization mass spectrometry
Description: After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Surgical treatment will occur within 24-hours following completion of therapy.
Study: NCT01471678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5mg)
Description: This study is an open-label, randomized, single dose, four-period cross-over study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)
Description: FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)
Description: FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)
Description: a commercial formulation of dutasteride plus tamsulosin HCl (Harnal-D Tablet); (4): a commercial formulation of dutasteride plus tamsulosin HCl(Harnal Capsule). Each dosing session will be separated by a wash-out period of 5 to 10 days
Study: NCT04121975

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 30 mg/d was administered on days 1-5 every two weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 30-40 mg/m2 was administered day 1, 8, 15, 22 and 29.
Study: NCT01686308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yellow Intra Ocular Lens (IOL)
Description: Standard operation with blue light filter Yellow IOL implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Intra Ocular Lens (IOL)
Description: Standard operation with conventional IOL implantation
Study: NCT01555450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Insured people receive firstly a letter to inform them that a patient navigator is available to navigate them during the colorectal screening steps. A free telephone number and the navigator schedule is given. After a minimum of one week the patient navigator begins the telephone outreach.
Study: NCT00334958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
Study: NCT00906529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levemir (Detemir) and Novolog (Aspart) Insulin
Description: Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levemir (Detemir) and Novolog (Aspart) Insulin
Description: Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
Study: NCT01869946

Intervention type: DRUG
Intervention: Ropivacaine
Study: NCT02979808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navina Smart
Description: Subjects treatment-naïve to transanal irrigation (TAI). Frequency of TAI will be tailored to each subject.
Study: NCT00869011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
Study: NCT00117936

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose
Description: Up to ten intramyocardial injections of low dose FGF 1-141, via a NOGA Injection Catheter, single cath lab session

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose
Description: Up to ten intramyocardial injections of high dose group (FGF-1-141), via a NOGA Injection Catheter, single cath lab session

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Up to ten intramyocardial injections of placebo via a NOGA Injection Catheter, single cath lab session
Study: NCT05283447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Medicine
Description: The clinical protocol subject to analysis for the intervention group consists of manual approach techniques for the myofascial and viscerofascial structures of the anterior face of the neck, maneuvers for the mediastinal region, techniques for normalizing the tone of the thoracic diaphragm and its pillars, on the peritoneal ligaments, and caudal traction of the stomach for manual correction of hiatal hernia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The physiotherapeutic treatment on the control group consists of an approach to the lumbopelvic joint restrictions and a massage on the inframesocolic abdominal region with minimal pressure, which does not affect the activity and position of the stomach.
Study: NCT02146716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energetic Resonance by Cutaneous Stimulation
Description: Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.
Study: NCT01444417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10\^9/L and ≤ 200 x 10\^9/L.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered by subcutaneous injection
Study: NCT01836133

Intervention type: DRUG
Intervention: Erlotinib 150 mg
Study: NCT03107546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalomatrix
Description: We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.

Intervention type: OTHER
Group type: OTHER
Intervention: Skin graft
Description: We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
Study: NCT03096847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Premenopausal patients additionally received goserelin 3.6mg as monthly implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Premenopausal patients additionally received goserelin 3.6mg as monthly implant
Study: NCT06168435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eIMPAQc
Description: e-IMPAQc has five main components: 1) primary and secondary standardized e-PRO questionnaires and algorithm; 2) summary report for clinicians with alert system; 3) summary report for patients, with tailored notifications regarding symptom severity; 4) self-management fact sheets library; and 5) clinical dashboard.
Study: NCT03072199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiTUXimab Injection
Description: Single dose of Rituximab given intravenously within 48hours of myocardial infarction
Study: NCT02159170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGF injection
Description: single injection of NGF into the volar forearm / single injection of NaCl into the volar forearm
Study: NCT03968198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous ASC (for Adipose-derived Stem/Stroma Cell)
Description: After adipose tissue aspiration (liposuction) by an authorized person, ASCs were isolated and cultured during 14±2 days by the French Blood Establishment. Then, patients receive intramuscular injections of ASCs.
Study: NCT02274207

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT application
Description: NPWT mode is cyclic mode : -125\~-50 mmHg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPWT application
Description: NPWT mode is cyclic mode : -125\~-50 mmHg
Study: NCT01300923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate
Study: NCT01440439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Use of insulin glargine as basal insulin for treatment of Type 1 Diabetes Mellitus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir
Description: Use of insulin detemir as basal insulin for treatment of Type 1 Diabetes Mellitus
Study: NCT02041936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife IRE System
Study: NCT01714375

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QuietDose Device
Description: The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise dose, as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QuietDose Device
Description: The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise dose, as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss.
Study: NCT01698775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Participants with moderate renal insufficiency will receive one omarigliptin 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one omarigliptin 12.5 mg capsule orally once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to omarigliptin
Description: Matching placebo to omarigliptin capsule administered orally once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide
Description: Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glipizide
Description: Matching placebo to glipizide daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to glipizide
Description: Matching placebo to glipizide daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
Study: NCT01372241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay health advisor visits and newsletter
Description: The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
Study: NCT06456619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tooth restoration
Description: Comparison of composite resin and CAD-CAM supported restorations for hypomineralized molar teeth in children

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tooth restoration
Description: Comparison of composite resin and CAD-CAM supported restorations for hypomineralized molar teeth in children
Study: NCT01946776

Intervention type: DEVICE
Group type: OTHER
Intervention: implantable heart rate monitor
Description: Implantation of Reveal XT
Study: NCT03977974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01736436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with APG101
Description: Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow collection
Description: During the study, bone marrow will be collected 4 times to assess study objectives

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood drawings
Description: During the study, blood will be drawn at different time points to assess study objectives
Study: NCT02428686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta (NeoRecormon)
Description: Epoetin beta 60 000 IU/week
Study: NCT01775969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: A text message with instructions is sent to the patient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voicemail
Description: A voicemail with instructions is sent to the patient
Study: NCT00767338

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Timed intercourse
Description: Timed intercourse

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Timed intercourse
Description: Timed intercourse

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Timed intercourse
Description: Timed intercourse

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Timed intercourse
Description: Timed intercourse

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microsurgical varicocelectomy
Description: Microsurgical varicocelectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microsurgical varicocelectomy
Description: Microsurgical varicocelectomy
Study: NCT02271529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® PTX® Drug-Eluting Peripheral Stent
Description: Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
Study: NCT00569933

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Audio recording
Description: Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
Study: NCT01250054

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lens
Description: Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lens
Description: Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
Study: NCT01227785

Intervention type: DEVICE
Intervention: INCEPTA ICD or CRT-D
Study: NCT03637491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: IV treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: IV treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Oral treatment